Summary

The global fill finish manufacturing market is estimated to reach USD 30.37 billion by 2031, up from USD 19.75 billion in 2026, at a CAGR of 9.0% from 2026 to 2031. Market growth is driven by the expanding biologics, biosimilars, vaccines, and injectable drug pipelines, increasing outsourcing to CDMOs, and rising demand for sterile manufacturing capacity. Technological advancements in aseptic filling, isolator systems, robotics, and ready-to-use components are further supporting market expansion. However, high capital investment requirements, stringent regulatory compliance standards, operational complexity, and skilled workforce shortages may restrain market growth to some extent.

"The consumables segment accounted for the largest market share, by product, in 2025."
Based on product, the fill finish manufacturing market is broadly segmented into consumables and instruments. In 2025, the consumables accounted for the largest market share, driven by their extensive use across filling, containment, inspection, and packaging operations. Consumables such as vials, prefilled syringes, cartridges, stoppers, seals, and other container & closure components are required for every production batch, creating recurring demand. The growing production of biologics, biosimilars, vaccines, and advanced therapies, coupled with increasing adoption of ready-to-use and single-use technologies, continues to drive strong demand for consumables across pharmaceutical companies and CDMOs globally.
"Contract manufacturing organization accounted for the largest share of the fill finish manufacturing market, by end user, in 2025."
Based on end user, the global fill finish manufacturing market is segmented into CMO, pharmaceutical and biopharmaceutical companies, and other end users. The CMOs segment accounted for the largest share of the global fill finish manufacturing market. Growth is driven by increasing outsourcing of sterile manufacturing operations by pharmaceutical and biotechnology companies seeking to reduce costs, access specialized expertise, and accelerate product commercialization. CMOs offer advanced aseptic processing capabilities, flexible production capacity, and strong regulatory compliance, making them preferred partners for biologics, biosimilars, vaccines, and injectable drugs. Rising demand for scalable and high-quality manufacturing services continues to strengthen their position in the market.
"Asia Pacific is projected to register the highest CAGR in the fill finish manufacturing market from 2026 to 2031."
The fill finish manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, the Asia Pacific region is estimated to grow at the highest CAGR, driven by expanding biopharmaceutical manufacturing, increasing investments in sterile injectable production, and rising demand for biologics, biosimilars, and vaccines. Growth is further supported by the rapid expansion of CDMO services, increasing adoption of advanced aseptic filling technologies, and ongoing investments in manufacturing infrastructure across China, India, South Korea, and Japan. The presence of major regional manufacturing hubs and continuous capacity expansions continues to strengthen the region's position in the global fill-finish manufacturing market.

The primary interviews conducted for this report can be categorized as follows:

・By Respondent: Supply Side - 70% and Demand Side - 30%
・By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
・By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25%
・By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, and the Middle East - 5%

List of Companies Profiled in the Report
・West Pharmaceutical Services Inc.
・BD & Co
・Syntegon Technology GmbH
・I.M.A. S.P.A.
・Gerresheimer AG
・AptarGroup Inc.
・Dätwyler Holding Inc.
・Danaher
・Stevanato Group S.p.A.
・OPTIMA
・Bausch+Ströbel
・Groninger & Co. GmbH
・SCHOTT
・Nipro Corporation
・Bausch Advanced Technology Group
・Maquinaria Industrial Dara SI

Research Coverage
This research report categorizes the fill finish manufacturing market by product, type, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the fill finish manufacturing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the fill finish manufacturing market. This report covers competitive analysis of top players and upcoming startups in the fill finish manufacturing market ecosystem.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall fill finish manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
・Analysis of key drivers (GLP-1/ Incretin Injectables for obesity driving demand outpacing capacity, Biosimilars & ADC pipeline expansion driving sterile injectable contract manufacturing growth, EU GMP Annex 1 compliance & global sterile manufacturing regulatory harmonization driving capital investments for isolator and RABS, robotics, automation & gloveless isolator technologies gaining traction with improved efficiency), restraints (Price pressure in sterile generics and hospital injectables, Workforce constraints in sterile manufacturing operations, High Capex and lead times constraining fill finish capacity addition, Oral peptides and GLP-1 drug delivery restraining fill finish volume growth), opportunities (Growing demand for cell & gene therapy/mRNA small batch manufacturing, Rising need for automated visual inspection and container closure integrity testing, Integration of predictive analytics, Radiopharmaceutical and Theranostic drug product fill-finish emerging as high growth niche segment) and challenges (Sustainability pressure and high energy intensity of sterile manufacturing) influencing the growth of fill finish manufacturing market
・Product Development/Innovation: Detailed insights on newly launched products of the fill finish manufacturing market
・Market Development: Comprehensive information about lucrative markets – the report analyses the fill finish manufacturing market across varied regions.
・Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the fill finish manufacturing market
・Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as West Pharmaceutical Services Inc. (US), BD & Co. (US), I.M.A S.p.A (Italy), Syntegon Technology GmbH (Germany), and Gerresheimer AG (Germany), among others

ページTOPに戻る

Table of Contents

1 INTRODUCTION 51
1.1 STUDY OBJECTIVES 51
1.2 MARKET DEFINITION 51
1.3 STUDY SCOPE 52
1.3.1 MARKETS COVERED AND REGIONS CONSIDERED 52
1.3.2 INCLUSIONS AND EXCLUSIONS 53
1.3.3 YEARS CONSIDERED 54
1.3.4 CURRENCY CONSIDERED 54
1.3.5 UNITS CONSIDERED 54
1.4 STAKEHOLDERS 54
1.5 SUMMARY OF CHANGES 55
2 EXECUTIVE SUMMARY 56
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 56
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 57
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 58
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 59
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 60
3 PREMIUM INSIGHTS 61
3.1 FILL-FINISH MANUFACTURING MARKET OVERVIEW 61
3.2 FILL-FINISH MANUFACTURING MARKET, BY TYPE & REGION 62
3.3 FILL-FINISH MANUFACTURING MARKET: GEOGRAPHIC SNAPSHOT 63
3.4 FILL-FINISH MANUFACTURING MARKET: BY TYPE, 2026 VS 2031 63
4 MARKET OVERVIEW 64
4.1 INTRODUCTION 64
4.2 MARKET DYNAMICS 64
4.2.1 DRIVERS 66
4.2.1.1 Rapid adoption of GLP-1/incretin injectables for obesity driving demand 66
4.2.1.2 Biosimilars & ADC pipeline expansion driving sterile injectable contract manufacturing growth 66
4.2.1.3 EU GMP Annex 1 compliance & global sterile manufacturing harmonization driving capital investment for isolators and RABS 66
4.2.1.4 Robotics, automation, and gloveless isolator technologies gaining traction 67
4.2.2 RESTRAINTS 67
4.2.2.1 Price pressure in sterile generics and hospital injectables 67
4.2.2.2 Workforce constraints in sterile manufacturing operations 67
4.2.2.3 High CapEx and long lead times constraining fill-finish capacity addition 68
4.2.2.4 Oral peptides and oral GLP-1 drug delivery restraining fill-finish volume growth 68
4.2.3 OPPORTUNITIES 68
4.2.3.1 Growing demand for cell & gene therapy/mRNA small-batch manufacturing 68
4.2.3.2 Rising need for automated visual inspection and container closure integrity testing 69
4.2.3.3 Integration of predictive analytics 69
4.2.3.4 Radiopharmaceutical and theranostic drug product fill-finish emerging as high-growth niche 69
4.2.4 CHALLENGES 69
4.2.4.1 Sustainability pressure and high energy intensity of sterile manufacturing 69
4.3 UNMET NEEDS AND WHITE SPACES 70
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 71
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 72
5 INDUSTRY TRENDS 73
5.1 PORTER’S FIVE FORCES ANALYSIS 73
5.1.1 THREAT OF NEW ENTRANTS 74
5.1.2 THREAT OF SUBSTITUTES 74
5.1.3 BARGAINING POWER OF BUYERS 74
5.1.4 BARGAINING POWER OF SUPPLIERS 74
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 75
5.2 MACROECONOMIC OUTLOOK 75
5.2.1 INTRODUCTION 75
5.2.2 GDP TRENDS AND FORECAST 75
5.2.3 TRENDS IN GLOBAL FILL-FINISH MANUFACTURING MARKET 76
5.3 VALUE CHAIN ANALYSIS 76
5.4 SUPPLY CHAIN ANALYSIS 78
5.5 ECOSYSTEM ANALYSIS 79
5.5.1 MANUFACTURING SITES, EXPANSIONS, AND CAPEX TRENDS OF KEY SUPPLIERS 81
5.5.2 MANUFACTURING SITES, EXPANSIONS, AND CAPEX TRENDS OF KEY FILL-FINISH CDMOS 81
5.6 PRICING ANALYSIS 87
5.6.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER (2025) 87
5.6.2 INDICATIVE SELLING PRICE, BY REGION, 2025 88
5.7 TRADE ANALYSIS 90
5.7.1 TRADE ANALYSIS FOR HS CODE 701010 90
5.7.2 TRADE ANALYSIS FOR HS CODE 3923 93
5.7.3 TRADE ANALYSIS FOR HS CODE 7017 96
5.7.4 TRADE ANALYSIS FOR HS CODE 401490 99
5.8 KEY CONFERENCES & EVENTS 102
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 102
5.9.1 KEY LAUNCHES AND PIPELINE OF BIOSIMILARS, GLP-1, CGT, ADC & RADIOPHARMACEUTICALS 103
5.9.2 US FDA APPROVAL TRENDS OF DRUG APPROVALS, BY DOSAGE FORM 109
5.9.2.1 Injectable dosage forms 109
5.9.2.2 Subcutaneous vs. intramuscular biologics 110
5.10 INVESTMENT & FUNDING SCENARIO 111
5.11 IMPACT OF US TARIFFS—FILL-FINISH MANUFACTURING MARKET 111
5.11.1 INTRODUCTION 111
5.11.2 KEY TARIFF RATES 112
5.11.3 PRICE IMPACT ANALYSIS 113
5.11.4 IMPACT ON COUNTRIES/REGIONS 113
5.11.4.1 North America 113
5.11.4.2 Europe 114
5.11.4.3 Asia Pacific 114
5.11.5 IMPACT ON END-USE INDUSTRIES 115
5.11.5.1 CMOS 115
5.11.5.2 Pharmaceutical and biotechnology companies 115
5.11.5.3 Other end users 115
5.12 FILL-FINISH OUTSOURCING TRENDS 116
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 117
6.1 KEY TECHNOLOGIES 117
6.1.1 ASEPTIC PROCESSING 117
6.1.2 STERILIZATION 117
6.2 ADJACENT TECHNOLOGIES 117
6.2.1 SINGLE-USE SYSTEMS 117
6.2.2 INSPECTION AND QUALITY CONTROL 117
6.3 COMPLEMENTARY TECHNOLOGIES 118
6.3.1 AUTOMATION AND ROBOTICS 118
6.3.2 ISOLATOR TECHNOLOGY 118
6.4 TECHNOLOGY/PRODUCT ROADMAP 118
6.5 PATENT ANALYSIS 119
6.5.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR FILL-FINISH MANUFACTURING PATENTS, 2015–2025 119
6.6 FUTURE APPLICATIONS 120
 
6.7 IMPACT OF AI/GEN AI ON FILL-FINISH MANUFACTURING MARKET 121
6.7.1 TOP USE CASES AND MARKET POTENTIAL 122
6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN FILL-FINISH MANUFACTURING MARKET 123
6.7.3 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 123
6.7.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN FILL-FINISH MANUFACTURING MARKET 124
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 125
7.1 REGIONAL REGULATIONS AND COMPLIANCE 125
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 126
7.1.2 REGULATORY FRAMEWORK 129
7.1.3 INDUSTRY STANDARDS 131
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 132
7.3 CERTIFICATIONS, LABELING, & ECO-STANDARDS 132
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 134
8.1 DECISION-MAKING PROCESS 134
8.2 KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA 135
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 135
8.2.2 KEY BUYING CRITERIA FOR CONSUMABLES, BY END USER 135
8.2.3 KEY BUYING CRITERIA FOR INSTRUMENTS, BY END USER 137
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 138
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 139
8.5 MARKET PROFITABILITY 139
9 FILL-FINISH MANUFACTURING MARKET, BY PRODUCT 140
9.1 INTRODUCTION 141
9.2 CONSUMABLES 141
9.2.1 PREFILLED SYRINGES 145
9.2.1.1 Prefilled syringes, by component 149
9.2.1.1.1 Prefilled syringe systems & components 149
9.2.1.1.1.1 Rising demand for prefilled syringe systems to drive market growth 149
9.2.1.1.2 Plunger stoppers 153
9.2.1.1.2.1 Rising prevalence of chronic diseases to positively impact demand for prefilled syringe plunger stoppers 153
9.2.1.2 Prefilled syringes, by material 156
9.2.1.2.1 Glass 157
9.2.1.2.1.1 Rising adoption of glass-based delivery systems to strengthen market share in biologics and vaccines 157
 
9.2.1.2.2 Polymer 160
9.2.1.2.2.1 Surging demand for polymer prefilled syringes in biologics and home care 160
9.2.2 VIALS 163
9.2.2.1 Vials, by material 167
9.2.2.1.1 Glass 167
9.2.2.1.1.1 Growth in biologics and vaccinations to drive market growth 167
9.2.2.1.2 Polymer 171
9.2.2.1.2.1 Rising demand for break-resistant, low-leachable packaging solutions for sensitive biologics and high-value injectable drugs 171
9.2.2.2 Vials, by format 174
9.2.2.2.1 Bulk vials 175
9.2.2.2.1.1 Growing use of bulk vials to support high-volume fill-finish operations 175
9.2.2.2.2 RTU vials 175
9.2.2.2.2.1 Rising adoption of RTU vials to streamline aseptic fill-finish processes 175
9.2.3 VIAL STOPPERS 176
9.2.3.1 RTS/RFS vial stoppers 180
9.2.3.1.1 Growing preference for RTS and RFS stoppers to enhance fill-finish efficiency 180
9.2.3.2 RTU vial stoppers 183
9.2.3.2.1 Accelerated shift toward RTU vial stoppers for sterile manufacturing 183
9.2.4 CARTRIDGES 186
9.2.4.1 Rising cases of diabetes and autoimmune disorders to drive growth of cartridges 186
9.2.5 CELL THERAPY FILL-FINISH BAGS 189
9.2.5.1 Specialized fill-finish bags enable safe and sterile cell therapy delivery 189
9.2.6 CAPS 192
9.2.6.1 Crimp/press-fit caps 193
9.2.6.1.1 Rising adoption of crimp and press-fit vial caps to support container-closure integrity in sterile injectables 193
9.2.6.2 Push-fit caps 194
9.2.6.2.1 Growing use of push-fit vial caps to reduce crimping complexity and particle risk in sterile fill-finish 194
9.2.7 OTHER CONSUMABLES 195
9.3 INSTRUMENTS 198
9.3.1 INSTRUMENTS, BY SYSTEM TYPE 201
9.3.1.1 Integrated systems 201
9.3.1.1.1 Integrated systems, by format 205
9.3.1.1.1.1 Integrated vial filling lines 205
9.3.1.1.1.1.1 Increasing adoption of integrated vial filling lines to improve aseptic throughput and sterility assurance 205
9.3.1.1.1.2 Integrated prefilled syringe & cartridge filling lines 209
9.3.1.1.1.2.1 Increasing demand for integrated filling lines to support self-administered injectables 209
9.3.1.1.1.3 Other integrated systems 212
9.3.1.1.2 Integrated systems, by barrier technology 215
9.3.1.1.2.1 Integrated isolator-based filling systems 216
9.3.1.1.2.1.1 Increasing adoption of integrated isolator-based filling systems to strengthen sterility assurance 216
9.3.1.1.2.2 Integrated RABS-based filling systems 218
9.3.1.1.2.2.1 Continued use of integrated RABS-based filling systems to support flexible aseptic manufacturing 218
9.3.1.1.2.3 Gloveless robotic fill-finish systems 220
9.3.1.1.2.3.1 Rising deployment of gloveless robotic fill-finish systems to reduce interventions and product loss 220
9.3.1.1.2.4 Conventional cleanroom-based filling systems 222
9.3.1.1.2.4.1 Ongoing role of conventional cleanroom-based systems in cost-sensitive and legacy fill-finish operations 222
9.3.1.2 Standalone systems 224
9.3.1.2.1 Standalone filling machines 228
9.3.1.2.1.1 Growing use of standalone filling machines to support flexible clinical and commercial sterile production 228
9.3.1.2.2 Standalone stoppering, capping, and sealing machines 231
9.3.1.2.2.1 Rising demand for standalone stoppering, capping, and sealing machines to strengthen vial closure reliability 231
9.3.1.2.3 Standalone washing, sterilization, and depyrogenation equipment 234
9.3.1.2.3.1 Continued adoption of standalone washing, sterilization, and depyrogenation equipment to support contamination control 234
9.3.1.2.4 Standalone lyophilization equipment 238
9.3.1.2.4.1 Increasing need for standalone lyophilization equipment to support biologics and high-value injectable stability 238
9.3.1.2.5 Other standalone systems 241
9.3.2 INSTRUMENTS, BY MACHINE TYPE 244
9.3.2.1 Automated machines 244
9.3.2.1.1 Fully automated vial filling machines 248
9.3.2.1.1.1 Increasing use of fully automated vial filling machines to support high-throughput sterile injectable production 248
9.3.2.1.2 Fully automated prefilled syringe & cartridge filling machines 251
9.3.2.1.2.1 Rising demand for automated prefilled syringe and cartridge filling machines to support self-administered injectables 251
9.3.2.1.3 Automated stoppering, capping, and sealing machines 254
9.3.2.1.3.1 Growing adoption of automated stoppering, capping, and sealing machines to improve closure reliability 254
9.3.2.1.4 Automated washing, sterilization, and depyrogenation systems 257
9.3.2.1.4.1 Increasing deployment of automated washing, sterilization, and depyrogenation systems to strengthen contamination control 257
9.3.2.1.5 Other automated machines 260
9.3.2.2 Semi-automated and manual machines 263
9.3.2.2.1 Semi-automated vial, prefilled syringe, and cartridge filling machines 267
9.3.2.2.1.1 Continued use of semi-automated filling machines to support flexible small-batch manufacturing 267
9.3.2.2.2 Other semi-automated & manual machines 270
9.4 FILL-FINISH CDMO SERVICES 273
10 FILL-FINISH MANUFACTURING MARKET, BY END USER 277
10.1 INTRODUCTION 278
10.2 CMOS 278
10.2.1 GROWING RELIANCE ON CMOS AS KEY END USERS IN FILL-FINISH MANUFACTURING MARKET 278
10.3 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 282
10.3.1 INCREASING IN-HOUSE FILL-FINISH CAPABILITIES AMONG PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 282
10.4 OTHER END USERS 285
11 FILL-FINISH MANUFACTURING MARKET, BY REGION 289
11.1 INTRODUCTION 290
11.2 NORTH AMERICA 297
11.2.1 US 305
11.2.1.1 Rising number of pipeline products for fill-finish manufacturing to drive market 305
11.2.2 CANADA 311
11.2.2.1 Competitive business environment to boost market 311
11.3 EUROPE 317
11.3.1 GERMANY 325
11.3.1.1 Rising focus on clinical research and patent approvals to drive market 325
11.3.2 UK 331
11.3.2.1 Growth in biopharmaceutical industry to support market growth 331
11.3.3 FRANCE 337
11.3.3.1 Increasing focus on developing biologics to drive demand for fill-finish technologies 337
11.3.4 ITALY 343
11.3.4.1 Investments and advancements to drive market 343
11.3.5 SPAIN 349
11.3.5.1 Innovations in fill-finish manufacturing market to drive growth 349
11.3.6 SWITZERLAND 355
11.3.6.1 Outsourcing trends and collaboration with CMOs to drive growth 355
11.3.7 REST OF EUROPE 361
11.4 ASIA PACIFIC 367
11.4.1 CHINA 375
11.4.1.1 Increased investments in biologics and biosimilar drug research to drive market 375
11.4.2 JAPAN 381
11.4.2.1 Rise in aging population to drive demand for medications 381
11.4.3 INDIA 387
11.4.3.1 Large domestic consumption and export of generic drugs to drive market 387
11.4.4 SOUTH KOREA 393
11.4.4.1 Well-developed healthcare industry and presence of major pharmaceutical manufacturers to drive market 393
11.4.5 REST OF ASIA PACIFIC 399
11.5 LATIN AMERICA 405
11.5.1 BRAZIL 412
11.5.1.1 Strong manufacturing ecosystem to boost market 412
11.5.2 MEXICO 418
11.5.2.1 Government initiatives in healthcare industry to fuel demand for pharmaceutical products 418
11.5.3 REST OF LATIN AMERICA 423
11.6 MIDDLE EAST 429
11.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE GROWTH 429
11.6.2 GCC COUNTRIES 436
11.6.3 SAUDI ARABIA (KSA) 442
11.6.3.1 More comprehensive access to healthcare services to fuel demand for pharmaceuticals 442
11.6.4 UNITED ARAB EMIRATES (UAE) 448
11.6.4.1 Increasing initiatives for domestic pharmaceutical production to drive market 448
11.6.5 REST OF GCC COUNTRIES 454
11.6.6 REST OF MIDDLE EAST 459
11.7 AFRICA 465
11.7.1 GROWING COLLABORATIONS AND HIGH INCIDENCE OF DISEASES TO DRIVE MARKET 465
12 COMPETITIVE LANDSCAPE 472
12.1 OVERVIEW 472
12.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN FILL-FINISH MANUFACTURING MARKET, 2023−2026 472
12.3 REVENUE ANALYSIS, 2021-2025 473
12.4 MARKET SHARE ANALYSIS 474
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 478
12.5.1 STARS 478
12.5.2 EMERGING LEADERS 478
12.5.3 PERVASIVE PLAYERS 478
12.5.4 PARTICIPANTS 478
12.5.5 COMPETITIVE BENCHMARKING OF TOP PLAYERS, 2025 480
12.5.5.1 Company footprint 480
12.5.5.2 Region footprint 481
12.5.5.3 Product footprint 482
12.5.5.4 End-user footprint 483
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 484
12.6.1 PROGRESSIVE COMPANIES 484
12.6.2 RESPONSIVE COMPANIES 484
12.6.3 DYNAMIC COMPANIES 484
12.6.4 STARTING BLOCKS 485
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 486
12.6.5.1 Detailed list of key startups/SMEs 486
12.6.5.2 Competitive benchmarking of key startups/SMEs 487
12.7 VALUATION AND FINANCIAL METRICS OF FILL-FINISH MANUFACTURING MARKET VENDORS 488
12.7.1 FINANCIAL METRICS 488
12.7.2 COMPANY VALUATION 488
12.8 BRAND/PRODUCT COMPARISON 489
12.9 COMPETITIVE SCENARIO 490
12.9.1 PRODUCT LAUNCHES 490
12.9.2 DEALS 490
12.9.3 EXPANSIONS 491
13 COMPANY PROFILES 492
13.1 KEY PLAYERS 492
13.1.1 WEST PHARMACEUTICAL SERVICES, INC. 492
13.1.1.1 Business overview 492
13.1.1.2 Products/Services/Solutions offered 493
13.1.1.3 Recent developments 501
13.1.1.3.1 Product launches and approvals 501
13.1.1.3.2 Deals 501
13.1.1.3.3 Expansions 502
13.1.1.4 MnM view 502
13.1.1.4.1 Key strengths/Right to win 502
13.1.1.4.2 Strategic choices 502
13.1.1.4.3 Weaknesses & competitive threats 503
 
13.1.2 BECTON, DICKINSON, AND COMPANY 504
13.1.2.1 Business overview 504
13.1.2.2 Products/Services/Solutions offered 505
13.1.2.3 Recent developments 508
13.1.2.3.1 Product launches and approvals 508
13.1.2.3.2 Deals 508
13.1.2.3.3 Expansions 508
13.1.2.4 MnM view 509
13.1.2.4.1 Key strengths/Right to win 509
13.1.2.4.2 Strategic choices 509
13.1.2.4.3 Weaknesses & competitive threats 509
13.1.3 SYNTEGON TECHNOLOGY GMBH 510
13.1.3.1 Business overview 510
13.1.3.2 Products/Services/Solutions offered 510
13.1.3.3 Recent developments 520
13.1.3.3.1 Product launches and approvals 520
13.1.3.3.2 Deals 521
13.1.3.3.3 Expansions 521
13.1.3.3.4 Other developments 521
13.1.3.4 MnM view 522
13.1.3.4.1 Key strengths 522
13.1.3.4.2 Strategic choices 522
13.1.3.4.3 Weaknesses & competitive threats 522
13.1.4 I.M.A. S.P.A. 523
13.1.4.1 Business overview 523
13.1.4.2 Products/Services/Solutions offered 523
13.1.4.3 Recent developments 533
13.1.4.3.1 Product launches and approvals 533
13.1.4.3.2 Deals 533
13.1.4.4 MnM view 534
13.1.4.4.1 Key strengths/Right to win 534
13.1.4.4.2 Strategic choices 534
13.1.4.4.3 Weaknesses & competitive threats 534
13.1.5 STEVANATO GROUP S.P.A. 535
13.1.5.1 Business overview 535
13.1.5.2 Products/Services/Solutions offered 536
13.1.5.3 Recent developments 542
13.1.5.3.1 Product launches and approvals 542
13.1.5.3.2 Deals 543
13.1.5.4 MnM view 544
13.1.5.4.1 Key strengths/Right to win 544
13.1.5.4.2 Strategic choices 544
13.1.5.4.3 Weaknesses & competitive threats 544
13.1.6 GERRESHEIMER AG 545
13.1.6.1 Business overview 545
13.1.6.2 Products/Services/Solutions offered 546
13.1.6.3 Recent developments 551
13.1.6.3.1 Product launches and approvals 551
13.1.6.3.2 Deals 552
13.1.6.3.3 Expansions 553
13.1.7 APTARGROUP, INC. 554
13.1.7.1 Business overview 554
13.1.7.2 Products/Services/Solutions offered 555
13.1.7.3 Recent developments 558
13.1.7.3.1 Product launches and approvals 558
13.1.7.3.2 Deals 558
13.1.7.3.3 Expansions 559
13.1.8 DÄTWYLER HOLDING INC. 560
13.1.8.1 Business overview 560
13.1.8.2 Products/Services/Solutions offered 561
13.1.8.3 Recent developments 564
13.1.8.3.1 Product launches and approvals 564
13.1.8.3.2 Deals 564
13.1.9 DANAHER CORPORATION 565
13.1.9.1 Business overview 565
13.1.9.2 Products/Services/Solutions offered 566
13.1.9.3 Recent developments 567
13.1.9.3.1 Deals 567
13.1.10 OPTIMA 568
13.1.10.1 Business overview 568
13.1.10.2 Products/Services/Solutions offered 568
13.1.10.3 Recent developments 570
13.1.10.3.1 Expansions 570
13.1.11 BAUSCH+STRÖBEL 571
13.1.11.1 Business overview 571
13.1.11.2 Products/Services/Solutions offered 571
13.1.11.3 Recent developments 579
13.1.11.3.1 Product launches and approvals 579
13.1.12 GRONINGER & CO. GMBH 580
13.1.12.1 Business overview 580
13.1.12.2 Products/Services/Solutions offered 580
13.1.12.3 Recent developments 582
13.1.12.3.1 Expansions 582
 
13.1.13 SGD PHARMA 583
13.1.13.1 Business overview 583
13.1.13.2 Products/Services/Solutions offered 583
13.1.13.3 Recent developments 587
13.1.13.3.1 Deals 587
13.1.13.3.2 Expansions 588
13.1.14 SCHOTT PHARMA AG & CO. KGAA 589
13.1.14.1 Business overview 589
13.1.14.2 Products/Services/Solutions offered 590
13.1.14.3 Recent developments 595
13.1.14.3.1 Product launches and approvals 595
13.1.14.3.2 Deals 595
13.1.14.3.3 Expansions 596
13.1.15 NIPRO CORPORATION 597
13.1.15.1 Business overview 597
13.1.15.2 Products/Services/Solutions offered 598
13.1.15.3 Recent developments 600
13.1.15.3.1 Product launches and approvals 600
13.1.15.3.2 Expansions 600
13.1.16 BAUSCH ADVANCED TECHNOLOGY GROUP 601
13.1.16.1 Business overview 601
13.1.16.2 Products/Services/Solutions offered 601
13.1.16.3 Recent developments 604
13.1.16.3.1 Deals 604
13.1.17 MAQUINARIA INDUSTRIAL DARA, S.L. 605
13.1.17.1 Business overview 605
13.1.17.2 Products/Services/Solutions offered 605
13.1.17.3 Recent developments 606
13.1.17.3.1 Product launches and approvals 606
13.1.17.3.2 Deals 606
13.2 OTHER PLAYERS 607
13.2.1 STERILINE S.R.L. 607
13.2.2 AUTOMATED SYSTEMS OF TACOMA, LLC 608
13.2.3 WEILER ENGINEERING, INC. 609
13.2.4 FEDEGARI AUTOCLAVI S.P.A. 610
13.2.5 SHANDONG PHARMACEUTICAL GLASS 611
13.2.6 MITSUBISHI GAS CHEMICAL 612
13.2.7 TERUMO CORPORATION 613
13.2.8 SKAN AG 614
13.2.9 ATS LIFE SCIENCE SYSTEMS 615
13.2.10 CORNING INC. 616
13.2.11 CREDENCE MEDSYSTEMS 617
13.2.12 3P INNOVATION LTD. 618
13.2.13 COLANAR AG. 619
14 RESEARCH METHODOLOGY 620
14.1 RESEARCH DATA 620
14.1.1 SECONDARY DATA 621
14.1.2 PRIMARY DATA 621
14.2 MARKET ESTIMATION METHODOLOGY 623
14.2.1 MARKET SIZE ESTIMATION 623
14.2.2 INSIGHTS OF PRIMARY EXPERTS 626
14.2.3 TOP-DOWN APPROACH 627
14.3 MARKET GROWTH RATE PROJECTIONS 628
14.4 MARKET BREAKDOWN AND DATA TRIANGULATION 630
14.5 RESEARCH ASSUMPTIONS 631
14.6 RESEARCH LIMITATIONS 631
14.7 RISK ANALYSIS 632
15 APPENDIX 633
15.1 DISCUSSION GUIDE 633
15.2 CUSTOMIZATION OPTIONS 637
15.3 RELATED REPORTS 637
15.4 AUTHOR DETAILS 638